Document is current
Any future updates will be listed below
-
Authors
Raz, Noa
Eyal, Aharon M.
Mua, Holgar
Kalil, Salhab
Fahoum-Khalefa, Nardine
Catz, Or
Schroeder, Josh
Davidson, Elyad M.
- License Information
-
More Information
Article History
Received: 1 December 2025
Accepted: 19 August 2026
First Online: 9 October 2026
Declarations
Ethics approval and consent to participate: The trial protocol (0092–17-HMO) was designed by the principal investigator and approved by the Institutional Review Board of Hadassah. Written informed consent was obtained from all subjects.
Consent for publication: Not applicable.
Competing interests: Dr. NR, Prof. AME, and Dr. NFK are Bazelet employees. Study medications are marketed by Bazelet. However;Statistical analysis was done by an external statistician—Dr. Or Catz, who was blinded to study drug identity; Prof. Davidson, director of pain relief unit Hadassah, and Prof. Schroeder, director of spine surgery Hadassah, were responsible for trial conception and design even before Bazelet was involved and took overall responsibility for avoiding undue influence.
